H. D. Brooks

Mantle cell lymphoma: an overview of diagnostic and therapeutic advances

Michael E. Williams, T. Harris, H. D. Brooks, 2008 .

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

V. Papadimitrakopoulou, H. Tran, J. Wright, 2011, Cancer.

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

K. Foon, A. Yacoub, J. Bitran, 2016 .

PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA

A. Yacoub, F. Lansigan, J. Ricker, 2017 .

Evolving Treatment Paradigms in Non-Small Cell Lung Cancer

Edward S. Kim, K. Mileham, H. D. Brooks, 2012 .

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial

J. Burke, K. Kolibaba, D. Mahadevan, 2016, British journal of haematology.

Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).

K. Kolibaba, K. Foon, A. Yacoub, 2017 .